Wall Street must wait for later this week to find out more from Kempharm Inc. about FDA talks ahead and further steps with Apadaz (KP201/APAP) for pain, but meanwhile an advisory panel's vote against the compound's abuse-deterrent properties sent shares (NASDAQ:KMPH) into a tailspin Friday to close at $6.91, down $8.76, or 55.9 percent.